SCHEDULE 13G: Alta Partners LLC Discloses Significant 6.23% Stake in AEON Biopharma, Inc.
Beneficial Ownership Disclosure
Alta Partners LLC has filed a Schedule 13G, reporting beneficial ownership of 6.23% of AEON Biopharma, Inc.'s common stock, indicating a substantial institutional investment.
Summary
- Alta Partners LLC reported beneficial ownership of 629,614 shares of AEON Biopharma, Inc. Common Stock.
- This ownership represents 6.23% of the total class of securities.
- Alta Partners LLC holds sole voting power and sole dispositive power over all 629,614 shares.
- The filing confirms that the securities were not acquired or held for the purpose of changing or influencing the control of AEON Biopharma, Inc.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment by Alta Partners LLC, suggesting confidence in AEON Biopharma, Inc., though the document itself is purely a disclosure of ownership and does not contain operational or financial performance details.
Positives
- A significant institutional investor, Alta Partners LLC, has taken a substantial stake (over 5%) in AEON Biopharma, Inc., which could be interpreted as a vote of confidence in the company's prospects.
- The acquisition of shares was not for the purpose of changing or influencing control, suggesting a passive investment strategy by Alta Partners LLC.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding AEON Biopharma, Inc.'s future performance or strategic direction.
Industry Context
This filing highlights continued institutional interest in the biopharma sector, with Alta Partners LLC identifying AEON Biopharma, Inc. as a company warranting a significant passive investment.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may positively influence market sentiment and potentially the share price due to perceived validation of the company's value.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of event which requires filing of this statement |
| 03/10/2025 | Date of Schedule 13G filing |
Keywords
AEON Biopharma, Alta Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biopharma, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.